IL18 and colitis: In mouse colitis model, MCC950 was demonstrated to act on NLRP3 by inhibiting ASC oligomerization and caspase-1 dependent activation of IL-1β and IL-18, and reducing the levels of pro-inflammatory cytokines [51].